503Pharma Compliance Intelligence

JOIN FREE MEMBERS AREA | COMPLIANCE TRAINING | FORMULA LIBRARY

Welcome back to 503Pharma Compliance Intelligence.

This week: a Missouri 503B outsourcing facility with a February 2026 warning letter. This is their fourth 483 since 2018 and their second warning letter. In April 2025, they voluntarily recalled a fentanyl/ropivacaine epidural injectable due to lack of sterility assurance.

Let's get into it.

📋 THIS WEEK'S CASE

A 503B outsourcing facility in Missouri. FDA inspection March 2025. Warning letter issued February 2026. This is their fourth 483 since 2018 — and their second warning letter. In April 2025, they voluntarily recalled a fentanyl/ropivacaine epidural injectable due to lack of sterility assurance.

WHAT HAPPENED

This 503B has been compounding sterile injectables — fentanyl, vancomycin, ketamine — for hospitals and clinics across the country. FDA has inspected them four times in seven years. Every inspection found serious problems. The problems keep recurring.

The 2025 Inspection: What FDA Found

Observation 1: Cleaning agents sprayed near uncovered bulk drug solution.

An operator repeatedly sprayed a microfiber mop with sanitizing and sporicidal agents while non-sterile bulk drug solution sat nearby — covered only with aluminum foil. This was happening in the anteroom during routine cleaning. The bulk solution was later used to fill sterile finished products.

Observation 2: Products released despite microbial contamination.

FDA found that the facility approved and distributed products even when environmental monitoring recovered 1 CFU on operator gloves or sleeves in the ISO 5 area. No adequate product evaluation. No appropriate corrective action. Products shipped anyway.

Observation 3: Particles everywhere after cleaning.

White fiber-like particles and debris were observed on the floor of the ISO 7 cleanroom — where the laminar flow hoods are located — and in the anteroom. This was after area cleaning that included equipment, ceilings, walls, and floors. The cleaning process was generating contamination.

Observation 4: Textured wall surfaces in cleanroom.

Wall panels in the anteroom were textured, not smooth. Textured surfaces are difficult to clean and can harbor contamination. FDA noted the facility had not evaluated the risk or developed mitigation strategies.

Observation 5: Smoke studies still inadequate.

The facility's smoke study protocol and report didn't specify what production equipment was included during testing. FDA noted that turbulence around production equipment — like the repeater pump, a substantial piece of equipment inside the laminar flow hood — would persist. Without video evidence, FDA couldn't verify whether the issue was resolved.

Observation 6: Contradictory procedures for anteroom use.

The anteroom served double duty as both ISO 7 and ISO 8 space depending on whether sterile or non-sterile activities were happening. FDA found the facility's corrective action responses contradicted each other about the sequence of cleaning and gowning. One response said bulk solution moved into the ISO 7 room before a full clean; another said ISO 7 access requires full cleaning first.

The Recall

On April 15, 2025, the facility voluntarily recalled a lot of Fentanyl 500mcg/Ropivacaine HCl 250mg in 0.9% Sodium Chloride — labeled "For Epidural Use Only" — due to lack of sterility assurance.

This is a high-risk product. Epidural administration bypasses most of the body's natural defenses against infection.

BACKGROUND: FOUR INSPECTIONS SINCE 2018

Here's the history:

2018 — First 483. Serious deficiencies in sterile drug production. Vancomycin recall due to stability concerns. Warning letter issued March 2019.

2021 — Second 483. Smoke studies not representative of actual compounding. Environmental monitoring deficient. Operators not monitored during critical operations. Compounding continued without particle counter for multiple days.

2023 — Third 483. 8% HEPA filter leak found during certification — hood had been in use since June 2022. No deviation opened. No investigation into impact on products filled in that hood. Media fills not performed with actual container sizes used in production. Visual inspection qualification inadequate. Contaminated EM plates still used.

2025 — Fourth 483. Cleaning agents near bulk solution. Products released with contamination recovered. Particles on floors after cleaning. Inadequate smoke studies. Warning letter issued February 2026.

WHY THIS MATTERS FOR ALL OF US

1. Repeat citations are a red flag for systemic failure.

When FDA writes the same observation in 2021, 2023, and 2025 — smoke studies not representative of actual operations — it raises questions about CAPA effectiveness. If the same finding keeps appearing, the corrective action process may need re-evaluation.

2. 503B facilities have broad reach.

This isn't a retail pharmacy compounding for individual patients. 503B outsourcing facilities ship sterile injectables — fentanyl, vancomycin, ketamine — to hospitals and clinics nationwide. The patient exposure from a single quality failure is significantly larger than a traditional 503A.

3. Voluntary recalls are often the tip of the iceberg.

The fentanyl/ropivacaine epidural recall was one lot. But FDA's observations suggest systemic contamination risks — particles after cleaning, products released with EM contamination, dual-use anterooms with contradictory procedures. One recalled lot doesn't capture the full scope.

4. Documentation gaps stall resolution.

FDA couldn't fully evaluate several corrective actions because the facility didn't provide adequate documentation. Smoke study protocols that don't specify equipment. Container closure studies that don't test actual drug products. EM forms that don't match updated SOPs. Documentation gaps aren't minor — they prevent FDA from closing issues.

5. Facility design matters.

The manufacturer's technical data sheet for the wall panels said nothing about suitability for pharmaceutical cleanrooms. Textured surfaces are difficult to clean and can harbor contamination. Facility design decisions made early can create compliance challenges later.

🛡️ BUILDING SYSTEMS THAT CATCH THIS

Repeat 483s don't happen because people don't know the requirements. They happen because systems don't enforce them. Smoke studies get filed but not validated. EM excursions get documented but not investigated. CAPAs get written but not verified.

Here's how CompoundLearn helps you stay ahead:

Training Modules Build competency in environmental control with DP-3: Facility & Environmental Controls and DP-4: Quality Assurance Program — so your team understands what smoke studies actually need to demonstrate and how to run a CAPA process that closes the loop.

SOP Library Access ready-to-use procedures for environmental monitoring response, smoke study protocols, and CAPA verification workflows. Don't reinvent the wheel — customize proven templates.

Competencies Assign and track role-specific qualifications. Ensure the person reviewing EM data knows what 1 CFU on operator gloves requires. Document who's trained on what.

Templates Generate smoke study documentation, EM investigation forms, and CAPA closure records. Audit-ready records that take seconds to create.

Assessments Verify that your team can identify contamination risks and respond appropriately. Document the results automatically.

One unified system for training, documentation, and compliance.

A pattern of repeat 483s. Or a system that breaks the cycle.

[Explore CompoundLearn →]

✅ THIS WEEK'S ACTION ITEM

Pull your last three internal audits or self-inspections. Look for any observation that appeared more than once.

For each repeat finding:

• Was the original CAPA verified as effective?

• Did you check that the corrective action was still in place 90 days later?

• Is it documented?

If you're seeing the same findings year over year, you don't have a training problem. You have a CAPA effectiveness problem.

Reply and tell us: Was this useful? What would make it better?

✉️ That’s your 503Pharma Intel Brief. Our mission is to keep compounding professionals informed, prepared, and ahead of the curve.